PURPOSE - A prospective trial started in 2010, aiming at developing models for urinary toxicity and erectile dysfunction after radiotherapy for prostate cancer. This analysis is finalised at highlighting correlations between clinical/dosimetric factors and acute urinary specific symptoms, as measured by single questions of the International Prostate Symptom Score (IPSS).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
MATERIALS/METHODS - IPSS was prospectively collected before and at the end of radiotherapy; absolute weekly bladder dose-surface histograms (DSHw) were chosen as dosimetric descriptors. Relevant clinical factors were prospectively gathered. Backward feature selection was used to identify variables to be included in logistic models for moderate-severe (scores⩾4) urinary symptoms.
RESULTS - Complete data of 262 patients (120 conventional fractionation, 142 hypofractionation) were available. Smoking was a strong predictor for feeling of incomplete emptying, frequency, intermittency, urgency and straining; neoadjuvant hormonal therapy and use of antihypertensive drugs were risk factors for intermittency and weak stream, respectively. The baseline score was a major predictor for all symptoms with the exception of intermittency. DSHw were correlated to increased risk of frequency, intermittency, urgency and nocturia. Most models showed moderate-high discrimination (AUC≈0.60-0.79).
CONCLUSIONS - Smoking and other clinical and dosimetric factors predict for specific moderate-severe acute urinary symptoms; baseline condition heavily modulated the risk in most endpoints.
Radiother Oncol. 2015 Aug 11. pii: S0167-8140(15)00409-0. doi: 10.1016/j.radonc.2015.07.048. [Epub ahead of print]
Cozzarini C1, Rancati T2, Carillo V3, Civardi F4, Garibaldi E5, Franco P6, Avuzzi B7, Esposti CD8, Girelli G9, Iotti C10, Palorini F3, Vavassori V11, Valdagni R12, Fiorino C3.
1 Radiotherapy, San Raffaele Scientific Institute, Milano, Italy.
2 Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
3 Medical Physics, San Raffaele Scientific Institute, Milano, Italy.
4 Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
5 Radiotherapy, IRCCS-Candiolo, Italy.
6 Radiotherapy, Ospedale Regionale U.Parini-AUSL Valle d'Aosta, Italy.
7 Radiation Oncology 1,Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
8 Radiotherapy, Ospedale Bellaria, Bologna, Italy.
9 Radiotherapy, Ospedale ASL9, Ivrea, Italy.
10 Radiation Therapy Unit, Department of Oncology and Advanced Technology, ASMN Hospital IRCCS, Reggio Emilia, Italy.
11 Radiotherapy, Cliniche Gavazzeni-Humanitas, Bergamo, Italy.
12 Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Radiation Oncology 1,Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.